NCT03268876Active, not recruiting
The INFLUENCE of Cytoreduction on PRO in EOC
The INFLUENCE of Cytoreduction on Patient Reported Outcomes in Patients With Epithelial Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 9 Oct 2024
Brief summary (registry, in English)
Based on an improved understanding of how the extent of successful cytoreduction is influenced both by inherent tumor biological characteristics as well as the aggressiveness of the surgical approach this project aims to better define the value of cytoreduction and to use the knowledge gained to develop more individualized therapy and follow-up. This will be achieved through a translational biomedical research approach. Due to the research group's traditions clinical phenotyping, biomarker identification, and clinical trials will be the focus.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 70 (estimated)
- First submitted
- 29 Aug 2017
- Start date
- 3 Mar 2021
- Primary completion date
- 28 Dec 2025
- Lead sponsor
- Haukeland University Hospital
- Diseases
- Ovarian cancer
- NCT number
- NCT03268876
What you commit to
- Study type: Observational
- Planned participants: 70
- From 3 Mar 2021 to the primary completion date, 28 Dec 2025
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Advanced ovarian cancer submitted to neoadjuvant chemotherapy
- Severe cardiopulmonary disease
Age
- \< 18 years old
Other
- Borderline and non-epithelial ovarian tumors
- Stage \< II
- ECOG 3-4
- Pregnancy
- Patients participating in QoL intervention studies
Who the study is looking for
- Epithelial ovarian cancer
- Stage \> II
- ECOG \< II
- Treated with primary surgery followed by chemotherapy
- Willing to participate and to sign the informed consent
Age in the registry: 18 years to 100 years · Sex: Female
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Haukeland University Hospital Coordinator of this site? Confirm its status | Bergen | Norway | Unknown status |
| Sørlandet sykehus HF Coordinator of this site? Confirm its status | Kristiansand | Norway | Unknown status |
| Stavanger University Hospital Coordinator of this site? Confirm its status | Stavanger | Norway | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.